Loading
A phase 3 trial of Carboplatin and Etoposide in neuroendocrine tumours, run by Boehringer Ingelheim, now recruiting.
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy is a phase 3 interventional study registered as NCT07544654 by Boehringer Ingelheim, with 390 participants planned, started 2026-07-10 and due to reach its primary completion in 2029-12-13. Interventions recorded: Obrixtamig, Carboplatin, Etoposide and Ventana DLL3 RxDx assay.
Shares Obrixtamig, Boehringer Ingelheim, Extrapulmonary neuroendocrine carcinoma, Neuroendocrine tumours and the tag pipeline.
Shares Etoposide, Topoisomerase-I inhibitors (and ADC payloads), Cytotoxic chemotherapy and the tag pipeline.
Shares Obrixtamig, Extrapulmonary neuroendocrine carcinoma, Neuroendocrine tumours and the tag pipeline.
Shares Etoposide, Topoisomerase-I inhibitors (and ADC payloads), Carboplatin, Cytotoxic chemotherapy and the tag pipeline.
Shares Etoposide, Topoisomerase-I inhibitors (and ADC payloads), Platinum agents, Carboplatin and the tag pipeline.
Shares Topoisomerase-I inhibitors (and ADC payloads), Platinum agents, Carboplatin, Cytotoxic chemotherapy and the tag pipeline.
Shares Etoposide, Topoisomerase-I inhibitors (and ADC payloads), Cytotoxic chemotherapy and the tag pipeline.
Shares Platinum agents, Carboplatin, Cytotoxic chemotherapy and the tag pipeline.